Search results
Results from the WOW.Com Content Network
Fresenius Medical Care AG & Co. KGaA is a German healthcare company which provides kidney dialysis services through a network of 4,171 outpatient dialysis centers, serving 345,425 patients. [3] The company primarily treats end-stage renal disease (ESRD), which requires patients to undergo dialysis 3 times per week for the rest of their lives.
In February 2019, Fresenius Medical Care acquired NxStage, a US-based maker of in-home dialysis devices, for $2 billion. [24] [non-primary source needed] [25] Fresenius Kabi is a supplier of 0.9% sodium chloride Injection USP diluent for use with the Pfizer–BioNTech COVID-19 vaccine. [26]
Vifor Fresenius Medical Care Renal Pharma (VFMCRP), the joint company with Fresenius Medical Care since 2010, gives CSL Vifor access to a network of dialysis centers. [23] It is active in the treatment of chronic kidney disease (CKD), [ 31 ] chronic kidney disease-associated pruritus , [ 32 ] renal anemia [ 33 ] and hyperphosphatemia .
For premium support please call: 800-290-4726 more ways to reach us
Currently, three hemodialysis machines are used for home hemodialysis in the United States. They are made by B. Braun Melsungen, Fresenius and NxStage, a division of Fresenius Medical Care. The systems take different approaches to the process of dialysis. The B Braun is a standard hemodialysis machine and is used in-center and at home.
In 2023, the Department of Defense awarded Kuleana Technology, the University of Washington, and Brooke Army Medical Center, in San Antonio, Texas, a $4 million grant to conduct animal trials.
NxStage Medical, Inc. (/ ˈ n ɛ k ˌ s t eɪ dʒ / NEK-stayj [2]) is an American company that develops, manufactures, and markets systems for the treatment of chronic kidney disease, acute kidney injury, and hypervolemia. It is a subsidiary of Fresenius Medical Care. System One, a portable hemodialysis system, is the company's primary product. [1]
Schneider joined Fresenius in November 2001, when he was appointed chief financial officer of Fresenius Medical Care. From May 2003 until June 2016 he was CEO of the parent company Fresenius. Under Schneider's leadership of Fresenius, the number of employees more than tripled, revenue quadrupled and net income increased twelvefold. [4]